Dr Kevin Xu

BSc PhD
Director of Computational Pathology

Kevin is a senior biomedical data scientist/engineer and highly experienced medical device software product development manager with a focus in artificial intelligence (AI) and digital pathology. Before joining OCB, he was a Lead Software Engineer in Tactiq Limited (originated from GE Healthcare), led the software development and managed the CE-marking process of a number biomedical products including the world-fast PCR thermal cycler. Prior to that, he had been a research fellow in medical imaging in Nottingham University and a Senior Technical Consultant in Hewlett-Packard UK.

Mohammed Jamal

Investor Director for Plutus

Mr Jamal has over 18 years of experience in structuring, placement, trading, private equity and liquid Investing. Mr Jamal started his career at Morgan Stanley in the structured credit team in 2003. In 2009 Mr Jamal moved to Resource America a $15Bn credit fund to lead their business in Europe.In 2012 Mr Jamal founded Molton Street Capital a London based CLO, CDO and ABS trading company that traded over $3Bn.In 2016 Mr Jamal co-founded Forepont Capital Group, a leading life science Venture Capital fund with office in London, New York and ParisMr Jamal invested in more than 20 companies since 2012 and made multiple successful exits.Mr Jamal holds a Masters degree in Applied Mathematics and Computer Sciences from Ecole Centrale Paris (top French “ Grande Ecole” ) and an advanced degree (DEA) in Finance and Economics from La Sorbonne University in Paris.

BK Lee

Non-Executive Director

Mr. Lee is a professional investor with extensive experience in investing in biotech and technology. He was previously involved in foreign currency trading at the Bank of New York based in Seoul. He also served as President of Sudokwon Environment Co. Currently Mr. Lee is CEO of Muhan Corporation, a Seoul-based environmental company, and CEO of 29 Investment Corporation, an investment company in Vietnam.

Professor David Kerr

CBE MA MD DSc FRCP FRCGP FACP FESMO FMedSci
Chief Medical Officer

David is a senior clinician with more than 30 years experience in cancer treatment. He has a strong record in clinical research and has built numerous life sciences companies over the years, including Cobra, Therexsys, Oxford Cancer Biomarkers, IngenOx and SynOx Therapeutics. David contributes to Oxford as Professor of Cancer Medicine and Consultant Medical Oncologist, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. He is an Honorary Professor of Oncology in Sichuan, Suchow, Xiamen, Shanghai, Zhejiang and Oslo Universities. He has published over 400 papers and has an H-Index > 100 associated with over 50,000 citations, placing him in the top 1-2% of cancer researchers in the world. He was elected President of the European Society of Medical Oncology in 2010. He is Editor in Chief of The Oxford Textbooks of Oncology and Cancer Biology, was Editor in Chief of Annals of Oncology, established the Journal of Global Oncology and leads a new course in Oxford on Global Health Diplomacy.

Professor Nick La Thangue

MA MSc PhD FRSE FMedSci
Chief Executive Officer

Nick has over 30 years of experience in biotech, leadership, entrepreneurship, translational cancer science and drug development. He founded Prolifix focused on cell cycle therapeutics, where he acted as CSO and CEO until its merger with TopoTarget which led to a highly successful IPO. He founded Celleron Therapeutics and Argonaut Therapeutics, acting as CEO for each company, and led their merger in 2022 to form IngenOx. He has been CEO at IngenOx Therapeutics developing precision cancer drugs since the company was formed. Nick is Professor of Cancer Biology at Oxford University. He is a Fellow of the Royal Society of Edinburgh, the Academy of Medical Sciences, the European Academy of Cancer Science, the Lister Institute and Professorial Fellow of Linacre College Oxford. He has over 200 publications and is an inventor on an extensive number of patents.

About Us

Since its foundation, OCB has built a world class development team consisting of industry professionals, leading scientists and oncologists, and marketing executives retaining strong links to Oxford University and the NHS Trust.

Together OCB hasdeveloped pioneering biomarker technologies and products that put each individual patient at the centre of cancer treatment.

Management Team

Nick 1 Circle 05c71278304d3ab3aca05d7ca77eb36b Ae85uzhdmw1y

Nick LaThangue

BSc MSc PhD MA; Interim CEO, COO
Director and Founder

Learn More

David Kerr

CBE MD DSc FRCP (Glas, Lon, Edin) FRCGP FMedSci
CMO, Director & Founder

Learn More

Dr Kevin Xu

BSc PhD
Director of Computational Pathology

Learn More

Board

Mohammed Jamal

Investor Director for Plutus

Learn More

Nick LaThangue

BSc MSc PhD MA
COO, Executive Director

Learn More

David Kerr

CBE MD DSc FRCP (Glas, Lon, Edin) FRCGP FMedSci
ExecutiveDirector

Learn More

BK Lee

Non-Executive Director

Learn More

Be part of our future

We’re committed to improving the treatment landscape for cancer patients by continuing to push boundaries forwards towards personalised medicine and individual care plans driven by high-performance cancer diagnostic tests that rely on the most highly innovative and proprietary technologies.. Our technologies can not only help patients, but also reduce costs and save time for health services across the world.

If you would like to be part of our future, whether through investment or partnerships, we’d love to hear from you.

Shutterstock 461986816)image3 Tube&labtech

News & Press

Oxford Cancer Biomarkers announces first patient into its clinical study for its precision oncology OncoProg test for colorectal cancer

January 14, 2025

PRESS RELEASE: Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

April 3, 2023

PRESS RELEASE: OncoHelix and Oxford Cancer Biomarkers Enter into a Partnership to Offer Breakthrough Cancer Genetic Screening Test to Canadians

March 20, 2023

PRESS RELEASE: Oxford Cancer Biomarkers granted Artificial Intelligence in Health and Care Award

March 3, 2023

PRESS RELEASE: Oxford Cancer Biomarkers announces European expansion of life-saving chemotherapy toxicity test and independent, real-world evidence of patient benefit

September 26, 2022

PRESS RELEASE: Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board

January 6, 2022

Health Economics model for OncoProg® commissioned

July 30, 2021

PRESS RELEASE: OncoProg receives CE mark

July 19, 2021

PRESS RELEASE: Kyoung Mee Lee joins our Board of Directors

April 30, 2021